This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $130,337 to The Trustees of Columbia University in the City of New York to conduct research on understanding the regulation of extramedullary hematopoiesis (EMH) in the liver. The key research objectives are to: 1) characterize the cellular components of the hematopoietic stem cell (HSC) niche in the EMH liver, 2) identify which HSC clones initiate liver EMH using a novel CRISPR/Cas9 barcoding mouse model, and 3) investigate the role of the splicing regulator RBFOX2 in regulating liver EMH formation. The award period is from Jan 1, 2025 to Dec 31, 2026. The insights gained from this research are expected to have broader applications in understanding and manipulating the progression of various pathological processes involving EMH. The principal investigator will receive additional mentorship from experts in immunology, liver biology, epigenetics, and bioinformatics to develop their skills and transition to an independent research career.
Generated 2/25/25, 4:05 AM